Skip to main content
Premium Trial:

Request an Annual Quote

Exelixis Files Registration Statement to Raise Additional Funds

NEW YORK, July 30 – Exelixis of South San Francisco, Calif., has filed a shelf registration with the Securities and Exchange Commission to offer up to $150 million in common stock.

The company said it was considering raising additional funds to help support the development of cancer drug rebeccamycin, which it recently acquired from Bristol-Myers Squibb, as well as for other drug discovery and corporate activities.

Exelixis recently announced initiatives to expand its activities in two major disease areas: metabolic disorders and cancer. Last week the company said it was expanding its internal drug discovery efforts into metabolic diseases, including cardiovascular disease, diabetes, and obesity.

That announcement came one week after Exelixis announced a major push into oncology via the formation of a partnership with Bristol-Myers Squibb to identify genes associated with tumor suppression using its invertebrate and vertebrate gene knockout models.

Companies generally file shelf registrations when market conditions are poor. By filing the statement, a company lays the groundwork for issuing shares so that it can act quickly to raise fresh funds as soon as market conditions become more favorable.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.